The sports thaw: NFL, NBA, MLB and the quiet end of cannabis testing

The most consequential cannabis policy shift of the past five years has not happened at the Department of Justice. It has happened at the collective bargaining tables of American professional sports.

One by one — quietly, through contract negotiations and updated drug policies — every major North American sports league has either ended random cannabis testing, removed marijuana from its banned substances list entirely, or raised positive-test thresholds so high they effectively function as legalization.

A decade ago, a positive marijuana test could suspend an NBA star, void an NFL contract, or end a minor-leaguer's career. Today, NBA players are not tested. MLB treats cannabis "the same as alcohol." NFL players cannot be suspended for marijuana use alone. And every one of these changes has happened without significant public backlash.

---

The NBA: random testing, gone

The NBA's 2023 collective bargaining agreement — negotiated between the league and the National Basketball Players Association — eliminated random cannabis testing entirely. The agreement, running seven years, represents the most complete decoupling between cannabis use and professional basketball in league history.

Under the current CBA:

• Cannabis is not tested for randomly across the player population
• Players who test positive under specific circumstances receive treatment referrals, not discipline
• There are no suspensions for marijuana use under the current drug policy
• Teams can sponsor or be sponsored by cannabis-adjacent brands under certain conditions

The change was, in practical terms, a formal ratification of what was already happening. The league had stopped enforcing its existing cannabis policy in any meaningful way during the 2020–21 season, when random testing was suspended during the COVID-19 bubble. The 2023 CBA simply made the pause permanent.

---

MLB: cannabis treated like alcohol

Major League Baseball removed marijuana from its list of banned substances in 2019. The league's current approach treats cannabis the same way it treats alcohol: a substance players may use in their personal lives, subject to policies around public conduct and treatment programs for dependency.

Operationally:

• MLB does not test players for marijuana
• Cannabis testing programs focus exclusively on performance-enhancing substances and drugs of abuse in the traditional opioid/stimulant/cocaine sense
• In June 2022, MLB authorized team sponsorships for NSF-certified CBD products — products that have been independently verified to contain no psychoactive THC levels
• In April 2023, the Chicago Cubs became the first MLB team to sign a CBD sponsorship

The Cubs sponsorship was unthinkable five years prior. It would have violated both the league's product guidelines and the sport's entire branding posture. By 2023, it was a financial transaction that generated precisely zero public controversy.

---

The NFL: the highest-stakes shift

The NFL's cannabis policy shift is, in some ways, the most consequential of the three. Football's physical demands, the league's historical use of suspension as discipline, and the cultural center-of-gravity NFL football occupies in American sport all make league policy changes particularly loaded.

Under the NFL's current policy:

• The positive-test threshold for THC has been raised from 35 ng/mL to 150 ng/mL — a fourfold increase that effectively functions as decriminalization for recreational use
• The testing window has been compressed from roughly April through August to the first two weeks of training camp only
• Players cannot be suspended solely for a positive marijuana test
• The league is funding clinical research into CBD for pain management and concussion neuroprotection through a partnership with Canadian researchers

The research partnership is particularly significant. The NFL — whose concussion-related liability is one of the defining legal stories of modern American sports — is actively investing in cannabinoid science. That is a long way from the league's 2014 position, when players were routinely suspended for off-season marijuana use and receiving lifetime bans after repeat positive tests.

---

The CTE and pain management backdrop

Every one of these league-level policy shifts traces, to some degree, to the same underlying pressure: chronic traumatic encephalopathy, pain management, and the opioid crisis.

Professional athletes are injured. They are injured frequently, severely, and with cumulative effects that extend decades beyond their playing careers. The pharmaceutical pain management infrastructure that served these players through the 1990s and 2000s — built around opioid prescriptions, NSAIDs, and cortisone injections — has been comprehensively discredited. Opioid dependency has been identified as a cause of retired-athlete mortality across leagues.

Cannabis, particularly cannabinoids like CBD, has emerged in the scientific and athlete-advocacy conversation as a potential alternative. The evidence is not uniformly strong — rigorous clinical trial data on cannabinoid pain management remains a work in progress — but the directional case is compelling enough that the leagues themselves have begun funding the research.

That is a structural shift. Leagues do not fund research into substances they intend to keep banning.

---

The sponsorship question

The next frontier — and the one that will move most quickly if it moves — is cannabis brand sponsorship of teams and leagues.

Polling has consistently shown majority or plurality fan support for cannabis-brand partnerships with major sports franchises. A 2024 survey found majorities supporting CBD sponsorships and pluralities supporting adult-use THC brand sponsorships, depending on the league and demographic segment.

The regulatory barrier is primarily federal. Cannabis remains a Schedule I substance under federal law (the December 2025 rescheduling executive order notwithstanding), which limits broadcast advertising and national sponsorship mechanics. State-licensed cannabis brands cannot sponsor televised national broadcasts without navigating significant FCC and legal risks.

If Schedule III rescheduling is finalized — whenever that eventually happens — the sponsorship landscape changes materially. Team-level partnerships, broadcast advertising, and league-wide sponsorship deals all become structurally easier to execute.

The largest single beneficiary category of federal rescheduling may, in retrospect, turn out to be professional sports marketing budgets.

---

Why this matters beyond sports

The league-level cannabis policy thaw is culturally significant for reasons that extend beyond athletics.

Professional sports are one of the few American institutions that still command mass bipartisan attention. A cannabis policy shift at ESPN's front door, at the NFL draft, at MLB Opening Day, reaches audiences that cannabis-specific media cannot. When a Chicago Cubs broadcast shows a CBD sponsor logo, that impression registers with millions of viewers who do not read industry publications.

Cultural legitimacy precedes political legitimacy by a measurable interval. The leagues have extended cannabis cultural legitimacy on a scale that no single advocacy campaign could have produced. Congressional and regulatory movement — when it eventually arrives — will reflect ground that has already shifted.

---

The bottom line

The NBA ended random cannabis testing. MLB removed marijuana from its banned substances list and authorized team CBD sponsorships. The NFL raised its THC threshold to 150 ng/mL, eliminated off-season testing, and began funding cannabinoid research.

None of these changes made front-page news. None of them produced fan backlash. None of them were reversed.

That is what the end of a cultural prohibition looks like from the inside: a series of collective bargaining agreements, a few commissioner's statements, a CBD sponsorship announcement, and the quiet disappearance of a policy that once ended careers.